Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
ONDANSETRON INJECTION, USP 40 mg/20 mL (2 mg/mL) 20 mL VIAL
Medication labelWhy this: Advisory · dailymed-prescription
Prevention of Nausea and Vomiting Associated with Initial and Repeat Courses of Emetogenic Cancer Chemotherapy Ondansetron injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Ondansetron is approved for patients aged 6 months and older. Prevention of Postoperative Nausea and/or Vomiting Ondansetron injection is indicated for the prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients in whom nausea and/or vomiting must be avoided postoperatively, ondansetron injection is recommended even when the incidence of postoperative nausea and/or vomiting is low. For patients who do not receive prophylactic ondansetron injection and experience nausea and/or vomiting postoperatively, ondansetron injection may be given to prevent further episodes. Ondansetron is approved for patients aged 1 month and older.
- generic_name
- ondansetron
- product_names
- ONDANSETRON
- ndc
- 51662-1377, 63323-374, 51662-1377-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en